Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 2Phase 2 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Breast 4Plasma cell 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Pain 4Neoplasm Metastasis 4Bone Neoplasms 4

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Ibandronic Acid × Sarcoma × Clear all
NCT00099177 2017-08-16

A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain

Hoffmann-La Roche

Phase 3 Terminated
96 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

NCT00099203 2017-08-16

A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease

Hoffmann-La Roche

Phase 3 Terminated
163 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

NCT02561039 2016-11-02

A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease

Hoffmann-La Roche

Phase 3 Completed
97 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

NCT02716792 2016-03-23

A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
334 enrolled
Sarcoma

Bone Neoplasms, Neoplasm Metastasis, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡